Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Pain management

Fremanezumab safe and effective for preventing migraine over longer term, study suggests

Research published in Neurology indicates that preventive treatment with fremanezumab continues to benefit patients with migraine over the longer term.


The researchers concluded that fremanezumab provided a treatment option for patients with chronic or episodic migraine to reduce their pain and disability 

Patients with migraine continue to benefit from preventive treatment with fremanezumab over the longer term, with sustained reductions in monthly migraine and headache days, a 12-month study in Neurology has suggested (10 September 2020)[1].

The monoclonal antibody, which targets the calcitonin gene-related peptide pathway, was evaluated as a monthly or quarterly preventive therapy over 52 weeks in 1,890 patients with either chronic migraine (CM) or episodic migraine (EM).

The researchers found that both treatment regimens were well tolerated and demonstrated sustained improvements in monthly migraine days (CM quarterly, -7.2 days; CM monthly, -8.0 days; EM quarterly, -5.2 days; EM monthly, -5.1 days), headache days (CM quarterly, -6.4 days; CM monthly, -6.8 days; EM quarterly, -4.4 days; EM monthly, -4.2 days), and headache-related disability for up to 12 months.

Adverse events, such as injection-site reactions, were broadly in line with previous studies, with no clinically significant adverse event patterns observed. There were also no serious cardiovascular-related adverse events related to fremanezumab.

“Fremanezumab continues to change the landscape of migraine prevention and treatment and provides a treatment option for patients with EM or CM to reduce their pain and disability while improving their quality of life,” the researchers concluded.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2020.20208531

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.